Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Antivir Ther. 2014 Jun 10;20(2):149–155. doi: 10.3851/IMP2806

Table 2.

Population model parameter estimates using the VE model

Parameter V0
[Log10 IU/mL]		 εmax k
[d−1]		 δ
[d−1]
Severity
of liver
disease		 Non-
cirrhotic		 Compensated
cirrhosis		 Decompensated
cirrhosis #		 Non-
cirrhotic		 Compensated
cirrhosis		 Decompensated
cirrhosis
Estimate (Standard error S.E) 6.4 (0.3) 6.3 (0.6) 4.7 (0.8) 0.861 (0.047) 0.685 (0.064) 0.59 (0.098) 2.12 (0.18) 0.62 (0.05)
- p=0.68 p<0.0001 - p=0.032 p=0.03
Between-subject variability [%] (SE) 133 (20) 16.6 (3.7) 13.9 (9.7) 31.8 (6.4)

V0, HCV baseline viral load; εmax, maximal SIL efficacy; k, rate constant describing the time to reach maximal drug effectiveness, and δ the infected cell loss rate. Individual parameter estimates are shown in Table S2. p, p-value for the difference from the non-cirrhotic group (Wald test).